Lars Abrahmsen's most recent trade in Aprea Therapeutics Inc was a trade of 100,000 Stock Option (right to Buy) done . Disclosure was reported to the exchange on March 10, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 100,000 | 100,000 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 24,700 | 43,700 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 01 Oct 2021 | 50,000 | 69,000 (0%) | 0% | 0.9 | 46,000 | Common Stock |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 50,000 | 30,587 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.89 per share. | 01 Oct 2021 | 50,000 | 19,000 (0%) | 0% | 4.9 | 244,500 | Common Stock |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.97 per share. | 20 Sep 2021 | 25,000 | 19,000 (0%) | 0% | 5.0 | 124,250 | Common Stock |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 25,000 | 80,587 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 20 Sep 2021 | 25,000 | 44,000 (0%) | 0% | 0.9 | 23,000 | Common Stock |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 82,000 | 82,000 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 19,000 | 19,000 (0%) | 0% | 0 | Common Stock |